



Chief Pharmaceutical Inspector

IWSC.405.9.2020.ABU.1
WTC/0594_01_01/47

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC and Art. 80(5) of Directive 2001/82/EC as amended

Chief Pharmaceutical Inspector

/the Competent Authority of Poland/

confirms the following:

the manufacturer

NYSK Holdings LLCOP

Boris Trajkovski str. No. 73, 1000 Skopje, NORTH MACEDONIA

site address

NYSK Holdings LLCOP

Boris Trajkovski str. No. 73, 1000 Skopje, NORTH MACEDONIA

is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC and Art. 80(1) of Directive 2001/82/EC transposed in Pharmaceutical Law of 6th of September 2001 (Journal of Laws from 2019, item 499).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **09-13/12/2019** it is considered that it complies with the Good Manufacturing Practice requirements laid down in Directive 2003/94/EC, Directive 91/412/EEC and the principles of GMP for active substances referred to in Article 47 of Directive 2001/83/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMP. If it does not appear, please contact the issuing authority.

date: 2020 -03- 06

Chief Pharmaceutical Inspectorate
ul. Senatorska 12, 00-082 Warszawa, Poland
Tel. +48 22 635 99 51, fax. +48 22 635 99 57




Paweł Piotrowski
Chief Pharmaceutical Inspector

3 MANUFACTURING OPERATIONS – ACTIVE SUBSTANCES**Active Substance(s):**


- Cannabis extract

3.2	Extraction of Active Substance from Natural Sources
	3.2.1 Extraction of substance from plant source 3.2.5 Modification of extracted substance (from plant source) 3.2.6 Purification of extracted substance (from plant source)
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing



date: 2020 -03- 0 6

Chief Pharmaceutical Inspectorate
ul. Senatorska 12, 00-082 Warszawa, Poland
Tel. +48 22 635 99 51, fax. +48 22 635 99 57


Pawel Piotrowski
Chief Pharmaceutical Inspector